Stockscreener 앱 받기
66.34
2.55%
1.65
시장 영업 전:
66.80
0.46
+0.69%
Arcellx Inc 주식(ACLX)의 최신 뉴스
Citi initiates Arcellx stock with buy rating on cell therapy potential - Investing.com
Citi initiates Arcellx stock with buy rating on cell therapy potential By Investing.com - Investing.com South Africa
Cancer Cell Market Exclusive Report with Detailed Study Analysis | Abbott Laboratories, Cellectis, Arcellx, GE - newstrail.com
Citigroup Initiates Arcellx at Buy With $110 Price Target - MarketScreener
Arcellx initiated with a Buy at Citi - TipRanks
Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus
Aileen Fernandes | People on The MoveSan Francisco Business Times - The Business Journals
Aileen Fernandes - The Business Journals
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment - TipRanks
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential - TipRanks
ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus
Arcellx stock maintains buy rating at H.C. Wainwright on launch plans - Investing.com
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating - TipRanks
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning - TipRanks
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy - TipRanks
Rhumbline Advisers Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Transcript : Arcellx, Inc.Special Call - MarketScreener
(ACLX) Technical Data - news.stocktradersdaily.com
Arcellx’s SWOT analysis: CAR-T pioneer’s stock poised for myeloma market shake-up - Investing.com
arcellx director Kavita Patel sells shares worth $101,040 By Investing.com - Investing.com Nigeria
arcellx director Kavita Patel sells shares worth $101,040 - Investing.com
Brokers Set Expectations for Arcellx FY2026 Earnings - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Two Sigma Investments LP - Defense World
FY2026 EPS Estimates for Arcellx Lifted by Leerink Partnrs - Defense World
Squarepoint Ops LLC Sells 4,670 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx FY2029 EPS Forecast Raised by Leerink Partnrs - Defense World
Kalkine: Top NASDAQ Stocks Arcellx’s Role by Kalkine - Kalkine Media
Two Sigma Advisers LP Acquires 1,100 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Millennium Management LLC Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Ameriprise Financial Inc. Sells 945 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (ACLX) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 9,110 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc Holds Annual Stockholders Meeting - TipRanks
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Thinking Of Buying Arcellx Inc (NASDAQ: ACLX) Stock? Here’s What You Need To Know - Stocksregister
Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Bluefield Daily Telegraph
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Benzinga
Baron Discovery Fund Initiated a Position in Arcellx (ACLX) - Insider Monkey
BNP Paribas Financial Markets Makes New $1.53 Million Investment in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) Receives a Buy from Canaccord Genuity - The Globe and Mail
Mercer Global Advisors Inc. ADV Takes $278,000 Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Q1 2025 Financial Results - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Arcellx - Defense World
Insiders At Arcellx Sold US$2.6m In Stock, Alluding To Potential Weakness - simplywall.st
Promising Clinical Data and Strong Safety Profile Lead to Buy Rating for Arcellx Inc’s Anito-cel - TipRanks
Arcellx Inc’s Anito-cel Shows Promising Efficacy and Safety in Multiple Myeloma, Earning Buy Rating - TipRanks
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise - marketscreener.com
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Arcellx Inc’s Anito-cel Therapy - TipRanks
Arcellx Announces Positive Phase 2 Study Results - TipRanks
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - BioSpace
Arcellx Reports Positive Data From Phase 2 IMMagine-1 Study - Nasdaq
Arcellx announces data from iMMagine-1 study of anitocabtagene autoleucel - TipRanks
Arcellx, Inc. Announces New Positive Data for Its Immagine-1 Study in Patients with Relapsed And/Or Refractory Multiple Myeloma - marketscreener.com
1.45%
0.86%
자본화:
|
볼륨(24시간):